Waratah Capital Advisors’s ProKidney PROK Stock Holding History

Waratah Capital Advisors’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,555	Closed	-$253K	–	226
2021 Q4	$253K	Sell	25,555 -25,556	-50%	-$253K	﹤0.01%	198
2021 Q3	$501K	Buy	51,111 +1,111	+2%	+$10.9K	0.01%	194
2021 Q2	$505K	Buy	+50,000	New	+$506K	0.01%	189

Other funds holding PROK

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Waratah Capital Advisors's PROK Position: Q1 2022 in Review

Waratah Capital Advisors sold out of ProKidney (PROK) in Q1 2022, closing a stake of 25,555 shares — an estimated $253K sold.

Waratah Capital Advisors first reported a position in PROK in Q2 2021 and held it in 3 quarters. The position peaked at $505K in Q2 2021. 80 funds tracked by Wall St. Rank hold PROK as of Q1 2022.

Waratah Capital Advisors reported no remaining ProKidney position as of Q1 2022 after selling out during the quarter.
Waratah Capital Advisors sold 25,555 ProKidney shares in Q1 2022, an estimated $253K.
Waratah Capital Advisors first reported a position in ProKidney in Q2 2021 and held it in 3 quarters.
Waratah Capital Advisors's ProKidney position peaked at $505K in Q2 2021.
80 funds tracked by Wall St. Rank held ProKidney as of Q1 2022.

Based on Waratah Capital Advisors's 13F filing for Q1 2022, filed 9 May 2022.